ECE2019 Guided Posters Calcium and Bone 2 (11 abstracts)
1Belarusian State Medical University, Minsk, Belarus; 210th city clinical hospital, Minsk, Belarus; 3Republic Center of Endocrinology and Medical Rehabilitation, Minsk, Belarus; 4Department of Clinical Medicine and Surgery, Division of Endocrinology, University of Naples Federico II, Naples, Italy.
Background and aims: Diabetic osteopathy in patients with type 1 diabetes (T1DM) is obvious. However, approaches to its diagnosis are still ambiguous. Thus, the aim was to study the features of serum osteo-specific parameters and dual energy Xray absorptiometry (DXA) data in T1DM patients.
Materials and methods: 157 patients with T1DM (105 women, 52 males) (mean age: 32.5 (25.541.6) yrs, duration of DM: 13 (720) yrs, age of manifestation: 19 (1423) yrs, BMI: 23.43 (21.5525,70) kg/m2; HbA1c: 8.2 (7.68.9) %) and 98 (67 women, 31 men) controls, comparable in sex, age and anthropometric data. The research involved general clinic examination, serum bone-specific parameters, DXA (bone mineral density (BMD) and trabecular bone score (TBS) of lumbar spine). Zscore of 2.0 or less was regarded as «low bone mineral density».
Results: There were no significant differences in L1-L4 BMD and TBS in women compared with men: 1.16 (1.081.26 vs. 1.16 (1.081.28) g/sm2; (U=5506; P=0.694) and 1.40 (1.351.46) vs. 1.44 (1.371.49) (U=3230; P=0.097). Similar results were obtained in subgroups of T1DM patients and controls. There was a definite link between BMD (L1L4) and TBS (L1L4) r2=0.33, P<0.001. Low BMD was detected in 14.6% (23) of the surveyed patients with T1DM and 4.1% (4) of controls. T1DM patients compared to controls had lower BMD and TBS: BMD 1.14 (1.041.22) vs 1.23 (1.131.33) g/cm2; U=3606; P<0.001; TBS 1.39 (1.331.46) vs 1.45 (1.391.48); U=2775; P<0.001), T-score TBS −0.30 (−1.900.30) vs 0.10 (−1.0250.90); U=248.5; P=0.018; Z-score TBS −0.30 (0.000.50) vs. 0.15 (−0.501.00), U=617; P=0.092. In T1DM patients was established decreased alkaline phosphatase (77.98 (67.7885.18) vs 93.4 (75.58110.8) U/l; U=698; P<0.001) and osteocalcin (10.58 (8.0815.70) vs 19.73 (15.1626.30) ng/ml; U=545; P<0.001) compared with the control group. There were an increased osteoprotegerin levels (4.44 (3.385.77) vs 2.74 (2.153.54) pmol/l; U=94; P<0.001) and a decreased the RANKL/osteoprotegerin ratio (0.03 (0.020.06) vs 0.05 (0.040.07), U=155; P=0.017).
Conclusions: T1DM patients have decreased bone formation markers (alkaline phosphatase, osteocalcin) and elevated resorption markers (osteoprotegerin), which can lead to impaired mineralization (low BMD) and microstructure (low TBS).